Piper Sandler analyst Biren Amin lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $11 and keeps an Overweight ...
While the broader markets have rallied since Donald Trump’s election, the price action in some tech names has been quite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback